Onxeo collaborates with the Royal College of Surgeons in Ireland for research program on Beleodaq® derivatives
Onxeo (EU:ONXEO)
Graphique Historique de l'Action
1 Mois : De Juin 2016 à Juil 2016
Regulatory News:
Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ
Copenhagen: ONXEO), an innovative company specializing in the
development of orphan oncology therapeutics, today announced a
collaboration with the Royal College of Surgeons in Ireland (RCSI) for a
discovery-stage program on the derivatives of belinostat (Beleodaq®), a
histone deacetylase (HDAC) inhibitor.
This new collaboration program aims at optimizing the pharmacokinetic
profile of belinostat, in order to increase its lifetime, its efficacy
and its stability. In the end, the goal is to develop conjugate
molecules derived from belinostat and with distinctive features compared
to existing HDAC inhibitors, which may lead to new patent opportunities.
The research projects will be led by Pr. Celine Marmion, Associate
Professor of Bioinorganic Chemistry at RCSI and specialized in rational
drug design, synthesis and pharmacological evaluation of metal-based
anti-cancer agents.
According to the terms of the agreement, research costs will be shared
between Onxeo and RCSI. Onxeo will have an option to license RCSI’s
patents at negotiated rates. RCSI will lead compounds synthesis and in
vitro testing, and Onxeo will lead the in vivo studies.
“We are excited to partner with leading research institution such as
RCSI for this preclinical program which should allow us to develop new
compounds derived from belinostat. This will enable us to
strengthen our portfolio while capitalizing on the experience already
acquired with this product. Results of these researches are expected in
the course of 2017,” commented Judith Greciet, CEO of Onxeo.
The concept for such a derived conjugated belinostat was validated by
similar work described in a safety and efficacy presentation at the
American Society of Hematology (ASH) Annual Meeting in 2011.
About Onxeo
Onxeo is a leading developer of orphan oncology drugs. The Company is
focused on developing innovative therapeutics for rare cancers, one of
the fastest growing markets in the healthcare industry with high, unmet
medical needs. Onxeo’s vision is to become a global leader and pioneer
in oncology, with a focus on orphan or rare cancers, by developing
advanced, effective, and safe therapeutics designed to improve the lives
of patients. Onxeo’s comprehensive portfolio features a broad orphan
oncology pipeline, with four independent programs in various stages of
clinical development, including Onxeo’s first approved orphan oncology
drug, Beleodaq®. The Company is headquartered in Paris, France and has
approximately 50 employees. Onxeo is listed on Euronext in Paris, France
(Ticker: ONXEO, ISIN Code: FR0010095596) and Nasdaq Copenhagen, Denmark
(Ticker: ONXEO).
Onxeo’s orphan oncology products are:
Livatag® (Doxorubicin Transdrug™): Currently being evaluated in
a Phase III trial (ReLive) in patients with hepatocellular carcinoma
(primary liver cancer); and in combination with other cancer agents in
first-line HCC
Beleodaq® (belinostat): FDA-approved in the US in 2014 under
the agency’s accelerated approval program as a second-line treatment
for patients with peripheral T-cell lymphoma (PTCL) and currently
marketed by Onxeo’s partner in the US, Spectrum Pharmaceuticals;
belinostat in combination with other cancer agents is currently in
development in first-line treatment for patients with PTCL (BelCHOP)
and in other solid tumors
AsiDNA: The first-in-class siDNA (signal-interfering DNA) which
has successfully undergone a proof-of-concept Phase I trial in
metastatic melanoma
Validive® (Clonidine Lauriad®): Positive final results from a
Phase II trial in head and neck cancer patients with severe oral
mucositis
In addition, Onxeo has successfully developed and
registered two non-cancer products which are currently being
commercialized in the U.S. and Europe.
Learn more by visiting www.onxeo.com.
To receive our press releases and newsletters, please register on: http://www.onxeo.com/en/newsletter/
Follow
us on Twitter: @Onxeo_
Disclaimer
This communication expressly or implicitly contains certain
forward-looking statements concerning Onxeo and its business. Such
statements involve certain known and unknown risks, uncertainties and
other factors, which could cause the actual results, financial
condition, performance or achievements of Onxeo to be materially
different from any future results, performance or achievements expressed
or implied by such forward-looking statements. Onxeo is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise. For a discussion of risks and
uncertainties which could cause actual results, financial condition,
performance or achievements of Onxeo to differ from those contained in
the forward-looking statements, please refer to the Risk Factors
("Facteurs de Risque") section of the 2015 Reference Document filed with
the AMF on April 29, 2016, which is available on the AMF website (http://www.amf-france.org)
or on the company’s website (www.onxeo.com).
View source version on businesswire.com: http://www.businesswire.com/news/home/201607070062...
Onxeo S.A.
Judith Greciet, CEO
Nicolas Fellmann, CFO
+33
1 45 58 76 00
contact@onxeo.com
or
Alize
RP (France)
Caroline Carmagnol / Florence Portejoie, +33 6 64 18 99
59 / +33 6 47 38 90 04
onxeo@alizerp.com
or
The
Ruth Group (U.S.)
Kirsten Thomas / Lee Roth, +1-508-280-6592 /
+1-646-536-7012
kthomas@theruthgroup.com
/ lroth@theruthgroup.com
Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Premium
Renseignements sur la Discussion
Afficher tous les Messages
Retourner à la liste
Rafraîchir
Onxeo collaborates with the Royal College of Surgeons in Ireland for research program on Beleodaq® derivatives
Onxeo (EU:ONXEO)
Graphique Historique de l'Action
1 Mois : De Juin 2016 à Juil 2016
Regulatory News:
Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ
Copenhagen: ONXEO), an innovative company specializing in the
development of orphan oncology therapeutics, today announced a
collaboration with the Royal College of Surgeons in Ireland (RCSI) for a
discovery-stage program on the derivatives of belinostat (Beleodaq®), a
histone deacetylase (HDAC) inhibitor.
This new collaboration program aims at optimizing the pharmacokinetic
profile of belinostat, in order to increase its lifetime, its efficacy
and its stability. In the end, the goal is to develop conjugate
molecules derived from belinostat and with distinctive features compared
to existing HDAC inhibitors, which may lead to new patent opportunities.
The research projects will be led by Pr. Celine Marmion, Associate
Professor of Bioinorganic Chemistry at RCSI and specialized in rational
drug design, synthesis and pharmacological evaluation of metal-based
anti-cancer agents.
According to the terms of the agreement, research costs will be shared
between Onxeo and RCSI. Onxeo will have an option to license RCSI’s
patents at negotiated rates. RCSI will lead compounds synthesis and in
vitro testing, and Onxeo will lead the in vivo studies.
“We are excited to partner with leading research institution such as
RCSI for this preclinical program which should allow us to develop new
compounds derived from belinostat. This will enable us to
strengthen our portfolio while capitalizing on the experience already
acquired with this product. Results of these researches are expected in
the course of 2017,” commented Judith Greciet, CEO of Onxeo.
The concept for such a derived conjugated belinostat was validated by
similar work described in a safety and efficacy presentation at the
American Society of Hematology (ASH) Annual Meeting in 2011.
About Onxeo
Onxeo is a leading developer of orphan oncology drugs. The Company is
focused on developing innovative therapeutics for rare cancers, one of
the fastest growing markets in the healthcare industry with high, unmet
medical needs. Onxeo’s vision is to become a global leader and pioneer
in oncology, with a focus on orphan or rare cancers, by developing
advanced, effective, and safe therapeutics designed to improve the lives
of patients. Onxeo’s comprehensive portfolio features a broad orphan
oncology pipeline, with four independent programs in various stages of
clinical development, including Onxeo’s first approved orphan oncology
drug, Beleodaq®. The Company is headquartered in Paris, France and has
approximately 50 employees. Onxeo is listed on Euronext in Paris, France
(Ticker: ONXEO, ISIN Code: FR0010095596) and Nasdaq Copenhagen, Denmark
(Ticker: ONXEO).
Onxeo’s orphan oncology products are:
Livatag® (Doxorubicin Transdrug™): Currently being evaluated in
a Phase III trial (ReLive) in patients with hepatocellular carcinoma
(primary liver cancer); and in combination with other cancer agents in
first-line HCC
Beleodaq® (belinostat): FDA-approved in the US in 2014 under
the agency’s accelerated approval program as a second-line treatment
for patients with peripheral T-cell lymphoma (PTCL) and currently
marketed by Onxeo’s partner in the US, Spectrum Pharmaceuticals;
belinostat in combination with other cancer agents is currently in
development in first-line treatment for patients with PTCL (BelCHOP)
and in other solid tumors
AsiDNA: The first-in-class siDNA (signal-interfering DNA) which
has successfully undergone a proof-of-concept Phase I trial in
metastatic melanoma
Validive® (Clonidine Lauriad®): Positive final results from a
Phase II trial in head and neck cancer patients with severe oral
mucositis
In addition, Onxeo has successfully developed and
registered two non-cancer products which are currently being
commercialized in the U.S. and Europe.
Learn more by visiting www.onxeo.com.
To receive our press releases and newsletters, please register on: http://www.onxeo.com/en/newsletter/
Follow
us on Twitter: @Onxeo_
Disclaimer
This communication expressly or implicitly contains certain
forward-looking statements concerning Onxeo and its business. Such
statements involve certain known and unknown risks, uncertainties and
other factors, which could cause the actual results, financial
condition, performance or achievements of Onxeo to be materially
different from any future results, performance or achievements expressed
or implied by such forward-looking statements. Onxeo is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise. For a discussion of risks and
uncertainties which could cause actual results, financial condition,
performance or achievements of Onxeo to differ from those contained in
the forward-looking statements, please refer to the Risk Factors
("Facteurs de Risque") section of the 2015 Reference Document filed with
the AMF on April 29, 2016, which is available on the AMF website (http://www.amf-france.org)
or on the company’s website (www.onxeo.com).
View source version on businesswire.com: http://www.businesswire.com/news/home/201607070062...
Onxeo S.A.
Judith Greciet, CEO
Nicolas Fellmann, CFO
+33
1 45 58 76 00
contact@onxeo.com
or
Alize
RP (France)
Caroline Carmagnol / Florence Portejoie, +33 6 64 18 99
59 / +33 6 47 38 90 04
onxeo@alizerp.com
or
The
Ruth Group (U.S.)
Kirsten Thomas / Lee Roth, +1-508-280-6592 /
+1-646-536-7012
kthomas@theruthgroup.com
/ lroth@theruthgroup.com